![]() |
Market Research Report
Product code
1015843
Asia Pacific Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027 |
Asia Pacific Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027 |
Published: June 15, 2021
KBV Research
Content info: 81 Pages
Delivery time: 1-2 business days
|
The Asia Pacific Erythropoietin Drugs Market would witness market growth of 13.2% CAGR during the forecast period (2021-2027).
The increasing incidences of chronic diseases like cancer, end-stage renal diseases, and HIV are likely to boost the demand for EPO-stimulating agents. These diseases have the potential to cause anaemia. To control the increasing cases of anaemia, the demand for Erthropotin (EPO) drugs would witness a surge in the forthcoming years.
The molecular weight of erythropoietin is about 30,400 daltons. It is generated by mammalian cells in which the gene of the human erythropoietin gene is introduced. The product acts similar to natural erythropoietin and retains biological activity in the same manner as endogenous erythropoietin. Epoetin alfa biosimilar like Retacrit (epoetin alfa-epbx or epoetin zeta) has a formulation that allows more treatment options for patients suffering from anaemia.
In the Asia Pacific, EPO industry is flourishing due to a continuous increase in the incidence of chronic diseases. There is high demand for low-cost therapeutics in this region. Therefore, the Asia Pacific has attracted many companies for the development of biosimilars. They are focused on developing more biosimilars than any other place on the globe.
Moreover, supportive government initiatives will also provide better health amenities to the public in this region. It is expected to contribute to the EPO drug market growth. For example, the Japanese government's regulation stated that on the price of biosimilars, a discount of 30% should be given and making it available at subsidized prices to people who belong to the lower economic class.
The China market dominated the Asia Pacific Hematology Market by Country in 2020, thereby, achieving a market value of $191 million by 2027. The Japan market is showcasing a CAGR of 15.5% during (2021 - 2027). Additionally, The India market is poised to grow at a CAGR of 15.5% during (2021 - 2027).
Based on Drug Class, the market is segmented into Biologics and Biosimilars. Based on Product, the market is segmented into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and others. Based on Application, the market is segmented into Renal Diseases, Cancer, Hematology and Neurology. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson and Johnson, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., F. Hoffmann-La Roche Ltd., Biocon Limited, Intas Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., LG Corporation (LG Life Sciences Ltd.), and Celltrion, Inc.
Market Segments covered in the Report:
By Drug Class
By Product
By Application
By Country
Companies Profiled
Unique Offerings from KBV Research
List of Figures